WT6
MCID: WLM011
MIFTS: 37

Wilms Tumor 6 (WT6)

Categories: Blood diseases, Cancer diseases, Fetal diseases, Genetic diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Wilms Tumor 6

MalaCards integrated aliases for Wilms Tumor 6:

Name: Wilms Tumor 6 56 73 29 6
Wilms Tumor 6, Susceptibility to 56 73
Wilms Tumor, Susceptibility to 56 73
Wt6 56 73
Susceptibility to Wilms Tumor 6 73
Nephroblastoma 71
Wilms Tumor 56

Classifications:



External Ids:

OMIM 56 616806
OMIM Phenotypic Series 56 PS194070
MeSH 43 D009396
SNOMED-CT via HPO 68 25081006 302849000
UMLS 71 C0027708

Summaries for Wilms Tumor 6

UniProtKB/Swiss-Prot : 73 Wilms tumor 6: A pediatric malignancy of kidney, and the most common childhood abdominal malignancy. It is caused by the uncontrolled multiplication of renal stem, stromal, and epithelial cells.

MalaCards based summary : Wilms Tumor 6, also known as wilms tumor 6, susceptibility to, is related to wilms tumor 1 and wilms tumor, aniridia, genitourinary anomalies, and mental retardation syndrome, and has symptoms including abdominal pain An important gene associated with Wilms Tumor 6 is REST (RE1 Silencing Transcription Factor). The drugs Clotrimazole and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, bone and t cells, and related phenotype is nephroblastoma.

More information from OMIM: 616806 PS194070

Related Diseases for Wilms Tumor 6

Diseases in the Hereditary Wilms' Tumor family:

Wilms Tumor 1 Wilms Tumor 2
Wilms Tumor 3 Wilms Tumor 4
Wilms Tumor 5 Wilms Tumor 6
Familial Wilms Tumor 2

Diseases related to Wilms Tumor 6 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 677)
# Related Disease Score Top Affiliating Genes
1 wilms tumor 1 12.9
2 wilms tumor, aniridia, genitourinary anomalies, and mental retardation syndrome 12.9
3 cervical wilms' tumor 12.7
4 global developmental delay, lung cysts, overgrowth, and wilms tumor 12.6
5 wilms tumor 2 12.5
6 wilms tumor 4 12.5
7 hereditary wilms' tumor 12.5
8 epithelial predominant wilms' tumor 12.5
9 stromal predominant kidney wilms' tumor 12.5
10 perlman syndrome 12.5
11 denys-drash syndrome 12.5
12 renal wilms' tumor 12.5
13 wilms tumor 3 12.5
14 blastema predominant kidney wilms' tumor 12.5
15 familial wilms tumor 2 12.4
16 wilms tumor predisposition 12.4
17 wilms tumor, aniridia, genitourinary anomalies, mental retardation, and obesity syndrome 12.4
18 mixed cell type kidney wilms' tumor 12.3
19 metachronous kidney wilms' tumor 12.3
20 frasier syndrome 11.9
21 beckwith-wiedemann syndrome 11.8
22 mulibrey nanism 11.7
23 simpson-golabi-behmel syndrome 11.7
24 hyperparathyroidism 2 with jaw tumors 11.7
25 mosaic variegated aneuploidy syndrome 1 11.7
26 mosaic variegated aneuploidy syndrome 3 11.7
27 mosaic variegated aneuploidy syndrome 11.7
28 aniridia 1 11.7
29 hemihyperplasia, isolated 11.6
30 rhabdoid tumor predisposition syndrome 1 11.6
31 ovarian wilms' cancer 11.6
32 li-fraumeni syndrome 11.6
33 li-fraumeni syndrome 2 11.6
34 bohring-opitz syndrome 11.6
35 thauvin-robinet-faivre syndrome 11.6
36 wilms tumor 5 11.4
37 megalencephaly-capillary malformation-polymicrogyria syndrome 11.4
38 chromosome 2q37 deletion syndrome 11.2
39 mosaic variegated aneuploidy syndrome 2 11.2
40 neuroblastoma 10.7
41 leukemia 10.7
42 leukemia, acute myeloid 10.7
43 kidney cancer 10.7
44 myeloid leukemia 10.6
45 clear cell sarcoma 10.6
46 renal oncocytoma 10.6
47 nephroma 10.6
48 acute leukemia 10.6
49 rhabdoid cancer 10.6
50 myelodysplastic syndrome 10.5

Graphical network of the top 20 diseases related to Wilms Tumor 6:



Diseases related to Wilms Tumor 6

Symptoms & Phenotypes for Wilms Tumor 6

Human phenotypes related to Wilms Tumor 6:

31
# Description HPO Frequency HPO Source Accession
1 nephroblastoma 31 HP:0002667

Clinical features from OMIM:

616806

UMLS symptoms related to Wilms Tumor 6:


abdominal pain

Drugs & Therapeutics for Wilms Tumor 6

Drugs for Wilms Tumor 6 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 242)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
2
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
3
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
4
Vincristine Approved, Investigational Phase 4 57-22-7, 2068-78-2 5978
5
Doxorubicin Approved, Investigational Phase 4 23214-92-8 31703
6
Dactinomycin Approved, Investigational Phase 4 50-76-0 457193 2019
7
Epirubicin Approved Phase 4 56420-45-2 41867
8
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
9
Oxytetracycline Approved, Investigational, Vet_approved Phase 4 79-57-2 54715139 5280972
10
Pirarubicin Investigational Phase 4 72496-41-4
11 Antifungal Agents Phase 4
12 Hormones Phase 4
13 Hormone Antagonists Phase 4
14 Cytochrome P-450 Enzyme Inhibitors Phase 4
15 Cytochrome P-450 CYP3A Inhibitors Phase 4
16
Hydroxyitraconazole Phase 4
17
Liposomal doxorubicin Phase 4 31703
18 Tubulin Modulators Phase 4
19 Antibiotics, Antitubercular Phase 4
20 Antimitotic Agents Phase 4
21
Decitabine Approved, Investigational Phase 2, Phase 3 2353-33-5 451668
22
Sulfamethoxazole Approved Phase 3 723-46-6 5329
23
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
24
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
25
Captopril Approved Phase 3 62571-86-2 44093
26
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
27
Ribavirin Approved Phase 3 36791-04-5 37542
28
Palivizumab Approved, Investigational Phase 3 188039-54-5
29
Acyclovir Approved Phase 3 59277-89-3 2022
30
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
31
Etoposide Approved Phase 3 33419-42-0 36462
32
Sorafenib Approved, Investigational Phase 3 284461-73-0 216239 406563
33
Daunorubicin Approved Phase 3 20830-81-3 30323
34
Bortezomib Approved, Investigational Phase 3 179324-69-7 387447 93860
35
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
36
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
37
Histamine Approved, Investigational Phase 3 51-45-6 774
38
Cyproheptadine Approved Phase 3 129-03-3 2913
39
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
40
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
41
Asparagine Approved, Investigational, Nutraceutical Phase 3 70-47-3 6267
42 Immunoglobulins Phase 3
43 Antibodies Phase 3
44 Antibodies, Monoclonal Phase 3
45 Antihypertensive Agents Phase 3
46 Angiotensin-Converting Enzyme Inhibitors Phase 3
47 HIV Protease Inhibitors Phase 3
48
protease inhibitors Phase 3
49 valacyclovir Phase 3
50 Amebicides Phase 3

Interventional clinical trials:

(show top 50) (show all 217)
# Name Status NCT ID Phase Drugs
1 A Pharmacokinetic Study of Actinomycin-D and Vincristine in Children With Cancer Unknown status NCT00491946 Phase 4 Actinomycin-D;Vincristine
2 Clinical Study to Evaluate the Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Pediatric Solid Tumors Completed NCT00336531 Phase 4 itraconazole
3 A Multicenter, Randomized, Double-blind, Prospective Study to Evaluate the Efficacy and Safety of Vincristine, Dactinomycin/Cyclophosphamide Combination Therapy Combined With Liposomal Doxorubicin/Doxorubicin/Pharmorubicin/Pirarubicin in 0.5-14 Year Old Children With Nephroblastoma. Not yet recruiting NCT03892330 Phase 4 Vincristine;Oxytetracycline/ Cyclophosphamide;Liposomal doxorubicin;Doxorubicin;Pharmorubicin;Pirarubicin
4 Nephroblastoma Clinical Trial and Study Unknown status NCT00003804 Phase 3 vincristine sulfate
5 Nephroblastoma (Wilms Tumour) Clinical Trial And Study Unknown status NCT00047138 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
6 Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor Unknown status NCT00352534 Phase 3 vincristine sulfate;doxorubicin hydrochloride
7 Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome Unknown status NCT01809392 Phase 2, Phase 3 decitabine
8 Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors Unknown status NCT00379340 Phase 3 doxorubicin hydrochloride;liposomal vincristine sulfate;cyclophosphamide;etoposide
9 Prospective and Randomized Study of Fixed Versus Flexible Prophylactic Administration of Granulocyte Colony-Stimulating Factor (G-CSF) in Children With Cancer Unknown status NCT01987596 Phase 3
10 NATIONAL WILMS TUMOR STUDY-5 -- THERAPEUTIC TRIAL AND BIOLOGY STUDY Completed NCT00002611 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
11 Glutamic Acid to Decrease Vincristine Toxicity in Children With Cancer Completed NCT00369564 Phase 3 glutamic acid
12 Detection of Minimal Residual Disease in Newly Diagnosed Patients With Leukemia and Those Who Undergo a Bone Marrow Transplant Using the Wilms Tumor Suppressor Gene (WT1) as a Marker By RT-PCR Completed NCT00179829 Phase 2, Phase 3
13 National Wilms Tumor Study-5 -- Treatment of Relapsed Patients, A National Wilms Tumor Study Group Phase III Study Completed NCT00002610 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
14 A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
15 Phase III Study of Captopril in Patients Undergoing Autologous Bone Marrow/Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
16 A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients Completed NCT00003883 Phase 3 fluconazole;itraconazole
17 A Randomized Double-Blind Placebo-Controlled Phase III Study To Evaluate The Safety And Efficacy Of Palivizumab Combined With Aerosolized Ribavirin Compared To Ribavirin Alone To Treat RSV Pneumonia In Patients With Bone Marrow Transplants (BMT) Completed NCT00014391 Phase 3 ribavirin
18 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
19 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
20 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
21 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
22 Treatment for Patients With Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor Active, not recruiting NCT00945009 Phase 3 Doxorubicin Hydrochloride;Vincristine Sulfate
23 A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD Active, not recruiting NCT01371981 Phase 3 Asparaginase;Bortezomib;Cytarabine;Daunorubicin Hydrochloride;Etoposide;Mitoxantrone Hydrochloride;Sorafenib Tosylate
24 Randomized Open-label Non-inferiority Phase 3 Clinical Trial for Patients With a Stage IV Childhood Renal Tumor, Comparing Upfront Vincristine, Actinomycin-D and Doxorubicin (Standard Arm) With Upfront Vincristine, Carboplatin and Etoposide (Experimental Arm) Not yet recruiting NCT03669783 Phase 3 treatment Vincristin;treatment Actinomycin-D;treatment Doxorubicin;treatment Carboplatin;Etoposide
25 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
26 Therapeutic Efficacy of Wilms Tumor Gene (WT1) mRNA-electroporated Autologous Dendritic Cell Vaccination in Patients With Myeloid Malignancies and Multiple Myeloma: A Phase II Trial Unknown status NCT00965224 Phase 2
27 Protocol For The Treatment Of Relapsed And Refractory Wilms Tumour And Clear Cell Sarcoma Of The Kidney (CCSK) Unknown status NCT00025103 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;melphalan;vincristine sulfate
28 Therapeutic Efficacy of Wilms' Tumor Gene (WT1) mRNA-electroporated Autologous Dendritic Cell Vaccination in Patients With Solid Tumors: a Phase I/Feasibility Study Unknown status NCT01291420 Phase 1, Phase 2
29 A Randomized, Placebo-Controlled Pilot Study of Genistein Supplementation in Pediatric Cancer Patients Receiving Myelosuppressive Chemotherapy Unknown status NCT02624388 Phase 2 Genistein;Placebo
30 A Multiinstitutional Trial To Evaluate The Prophylactic Use Of NASA-Developed Light Emitting Diodes For The Prevention Of Oral Mucositis In Bone Marrow Transplant Patients Unknown status NCT00036712 Phase 2
31 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
32 A Phase II Trial of All-Trans-Retinoic Acid in Combination With Interferon-Alpha 2a in Children With Recurrent Neuroblastoma or Wilms' Tumor Completed NCT00001509 Phase 2 IFN-alpha with retinoic acid
33 A Phase II Study of Topotecan in Children With Recurrent Wilms Tumor Completed NCT00187031 Phase 2 Topotecan, Filgrastim (G-CSF), Pegfilgrastim
34 A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma Completed NCT01502410 Phase 2 sorafenib tosylate
35 Phase II Study of Arsenic Trioxide in Neuroblastoma and Other Pediatric Solid Tumors Completed NCT00024258 Phase 2 arsenic trioxide
36 Phase II Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Children and Young Adults With Refractory Solid Tumors Completed NCT00331643 Phase 2 ixabepilone
37 A Pilot Study of Tumor Lysate-pulsed Dendritic Cell Vaccine for Immune Augmentation for High-risk Solid Tumor Patients Following Autologous Stem Cell Transplantation Completed NCT00405327 Phase 2
38 Phase II Study of Cyclophosphamide, Doxorubicin, Vincristine, Etoposide, and Ifosfamide, Followed by Resection and Radiotherapy in Patients With Peripheral Primitive Neuroectodermal Tumors or Ewing's Sarcoma Completed NCT00002466 Phase 2 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
39 Myeloablative Chemotherapy With Stem Cell Rescue for Rare Poor-Prognosis Cancers Completed NCT00141765 Phase 2
40 A Pilot Study Investigating the Effects of Glutamine and Vincristine-Induced Neuropathy in Pediatric Patients With Cancer Completed NCT00365768 Phase 2 Glutamine
41 Phase II Pharmacokinetic Study to Assess the Age-dependency in the Clearance of Doxorubicin in Paediatric Patients With Solid Tumours and Leukaemia Completed NCT01095926 Phase 2 doxorubicin
42 A Phase I/II Trial of Temodar in Pediatric Patients and Young Adults With High-Risk or Recurrent Solid Tumors Completed NCT00005952 Phase 1, Phase 2 temozolomide
43 Treatment of High Risk Renal Tumors: A Groupwide Phase II Study Completed NCT00335556 Phase 2 Doxorubicin Hydrochloride;Irinotecan Hydrochloride;Cyclophosphamide;Etoposide;Carboplatin;Vincristine Sulfate
44 Myeloablative Chemotherapy With Bone Marrow Rescue For Rare Poor-Prognosis Cancers Completed NCT00002515 Phase 2 carboplatin;thiotepa;topotecan hydrochloride
45 A Phase I/IIA Dose-Escalating Trial of BCL-2 Antisense (G3139) Treatment for Patients With Androgen-Independent Prostate Cancer or Other Advanced Solid Tumor Malignancies Completed NCT00003103 Phase 1, Phase 2 docetaxel
46 Randomized Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy Completed NCT01265433 Phase 2
47 A Phase II Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, NSC #742460) in Children With Relapsed/Refractory Solid Tumors Completed NCT00831844 Phase 2
48 Phase II Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed Malignancies Completed NCT00038207 Phase 2 Liposomal Vincristine
49 Phase I/II Study of Adoptive Immunotherapy With CD8+ WT1-Specific CTL Clones for Patients With Advanced MDS, CML, AML or ALL After Allogeneic Hematopoietic Stem Cell Transplant Completed NCT00052520 Phase 1, Phase 2
50 Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation Completed NCT00309907 Phase 2 methylprednisolone

Search NIH Clinical Center for Wilms Tumor 6

Genetic Tests for Wilms Tumor 6

Genetic tests related to Wilms Tumor 6:

# Genetic test Affiliating Genes
1 Wilms Tumor 6 29 REST

Anatomical Context for Wilms Tumor 6

MalaCards organs/tissues related to Wilms Tumor 6:

40
Bone Marrow, Bone, T Cells, Myeloid, Kidney, Brain, Lung

Publications for Wilms Tumor 6

Articles related to Wilms Tumor 6:

# Title Authors PMID Year
1
Mutations in the transcriptional repressor REST predispose to Wilms tumor. 6 56
26551668 2015
2
Pulmonary metastasectomy in pediatric patients. 61
26837694 2016
3
Testicular sperm extraction combined with intracytoplasmic sperm injection in the treatment of men with persistent azoospermia postchemotherapy. 61
11745242 2001
4
A dose-intensive, cyclophosphamide-based regimen for the treatment of recurrent/progressive or advanced solid tumors of childhood: a report from the Australia and New Zealand Children's Cancer Study Group. 61
9241083 1997
5
Phase I study of tumor necrosis factor-alpha and actinomycin D in pediatric patients with cancer: a Children's Cancer Group study. 61
7804527 1994
6
Malignant tumors in children of northeastern Zaire. A comparison of distribution patterns. 61
2302907 1990

Variations for Wilms Tumor 6

ClinVar genetic disease variations for Wilms Tumor 6:

6 ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 REST NM_005612.5(REST):c.831_832del (p.Cys278fs)deletion risk factor 222002 rs869025310 4:57777635-57777636 4:56911469-56911470
2 REST NM_005612.5(REST):c.773_776del (p.Val258fs)deletion risk factor 222003 rs869025311 4:57777575-57777578 4:56911409-56911412
3 REST NM_005612.5(REST):c.965A>G (p.His322Arg)SNV risk factor 222004 rs869025312 4:57786019-57786019 4:56919853-56919853

UniProtKB/Swiss-Prot genetic disease variations for Wilms Tumor 6:

73
# Symbol AA change Variation ID SNP ID
1 REST p.Arg160Pro VAR_076333
2 REST p.Asn290Tyr VAR_076334
3 REST p.His322Arg VAR_076335 rs869025312
4 REST p.His412Gln VAR_076336

Expression for Wilms Tumor 6

Search GEO for disease gene expression data for Wilms Tumor 6.

Pathways for Wilms Tumor 6

GO Terms for Wilms Tumor 6

Sources for Wilms Tumor 6

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....